- Home
- ORKA vs PRME Comparison
ORKA vs PRME Comparison
Compare ORKA & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKA
- PRME
- Stock Information
- Founded
- ORKA 2004
- PRME 2019
- Country
- ORKA United States
- PRME United States
- Employees
- ORKA N/A
- PRME 214
- Industry
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PRME Medicinal Chemicals and Botanical Products
- Sector
- ORKA Health Care
- PRME Health Care
- Exchange
- ORKA Nasdaq
- PRME Nasdaq
- Market Cap
- ORKA 580.3M
- PRME 693.5M
- IPO Year
- ORKA N/A
- PRME 2022
- Fundamental
- Price
- ORKA $15.57
- PRME $4.06
- Analyst Decision
- ORKA Strong Buy
- PRME Buy
- Analyst Count
- ORKA 8
- PRME 6
- Target Price
- ORKA $40.43
- PRME $8.88
- AVG Volume (30 Days)
- ORKA 137.1K
- PRME 2.9M
- Earning Date
- ORKA 08-11-2025
- PRME 11-11-2025
- Dividend Yield
- ORKA N/A
- PRME N/A
- EPS Growth
- ORKA N/A
- PRME N/A
- EPS
- ORKA N/A
- PRME N/A
- Revenue
- ORKA N/A
- PRME $4,961,000.00
- Revenue This Year
- ORKA N/A
- PRME $179.58
- Revenue Next Year
- ORKA N/A
- PRME N/A
- P/E Ratio
- ORKA N/A
- PRME N/A
- Revenue Growth
- ORKA N/A
- PRME 739.42
- 52 Week Low
- ORKA $5.49
- PRME $1.11
- 52 Week High
- ORKA $31.13
- PRME $5.17
- Technical
- Relative Strength Index (RSI)
- ORKA 53.65
- PRME 58.09
- Support Level
- ORKA $15.52
- PRME $3.09
- Resistance Level
- ORKA $16.21
- PRME $4.18
- Average True Range (ATR)
- ORKA 0.90
- PRME 0.27
- MACD
- ORKA 0.01
- PRME 0.08
- Stochastic Oscillator
- ORKA 48.43
- PRME 86.70
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.